李書福:吉利絕不參與內卷式惡性競爭
內媒報道,吉利汽車(00175.HK)母公司吉利集團董事長李書福近日發表內部講話視頻,提及吉利將通過技術、品質、服務、品牌和道德等方面的競爭,實現全面的行業領先。集團無論如何都不會放棄傳統內燃機汽車的研發與製造,既堅持在智能電動化汽車產業發展方面加大投入,又要在傳統內燃機汽車及混合動力汽車方面堅持技術引領,持續投入。
他強調,吉利絕不參與內卷式惡性競爭,要打就打價值戰、技術戰,並認爲不斷堅持技術引領,才能在激烈的市場競爭中立於不敗之地。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.